Abstract
Cost-effectiveness analysis was conducted to estimate the monthly incremental cost of switching from basal insulin + oral antidiabetics (OADs) ± GLP-1 receptor agonist (GLP1-RA) to IDegLira based therapy and incremental monthly cost to achieve HbA1c reduction in 6 months after the switch.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Paper Title
Journal
Date
